Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Seres Therapeutics, Inc.MCRB · Entity 7191 | See Remarks | August 15, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Seres Therapeutics, Inc.
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,995 |
Ending reported balance
After 2026-08-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-15 · Exercise / conversion · Acquired 238 · Balance 8,076 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Row 2 · 2026-08-17 · Sale · Disposed 81 · Balance 7,995 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 282 |
Reported balance
After 2026-08-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-15 · Exercise / conversion · Disposed 140 · Balance 282 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 585 |
Reported balance
After 2026-08-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-15 · Exercise / conversion · Disposed 98 · Balance 585 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2024 Filed Feb 17, 2024 02:31 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 4,170 | $1.08 | $4,503.60 |
DisclosureSEC source: 0000950170-24-016695 · ownership.xml · nonDerivative · entry 2 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,436 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2024 Filed Feb 17, 2024 02:31 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016695 · ownership.xml · derivative · entry 6 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 11,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F7 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F7 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2024 Filed Feb 17, 2024 02:31 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 11,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-016695 · ownership.xml · nonDerivative · entry 1 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 02:31 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016695 · ownership.xml · derivative · entry 5 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F6 · derivative.exercise_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F6 · derivative.expiration_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 02:31 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 287,905 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0000950170-24-016695 · ownership.xml · derivative · entry 4 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 287,905 Underlying: Common Stock · 287,905 shares Expires 2034-02-13 F5 · derivative.exercise_date: The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 02:31 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 187,500 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0000950170-24-016695 · ownership.xml · derivative · entry 3 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2034-02-13 F4 · derivative.exercise_date: The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 01:36 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 3,886 | $1.35 | $5,246.10 |
DisclosureSEC source: 0000899243-23-020069 · doc4.xml · nonDerivative · entry 2 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,356 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs. F3 · price: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.35 to $1.385, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 27, 2023 Filed Nov 1, 2023 01:36 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 12,623 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020069 · doc4.xml · derivative · entry 4 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,622 Underlying: Common Stock · 12,623 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1 · shares: On February 3, 2023, the reporting person was granted an award of 25,245 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 12,623 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 12,622 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 25,245 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 12,623 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 12,622 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| October 27, 2023 Filed Nov 1, 2023 01:36 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 12,623 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020069 · doc4.xml · nonDerivative · entry 1 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 3, 2023, the reporting person was granted an award of 25,245 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 12,623 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 12,622 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. Read SEC document |
| April 27, 2023 Filed May 1, 2023 20:41 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $10.84 | $0.00 |
DisclosureSEC source: 0000899243-23-011942 · doc4.xml · derivative · entry 1 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 35,000 shares Expires 2027-06-18 F1 · balance_after: On June 19, 2017, the Reporting Person was granted an option to purchase 70,000 shares of the Issuer's common stock. The option vested and became exercisable in two equal installments upon the satisfaction of certain performance criteria. On April 27, 2023, the Issuer's Board of Directors determined that the performance criteria for the second installment were met, resulting in vesting of the option as to 35,000 shares. Read SEC document |
| April 27, 2023 Filed Nov 1, 2023 01:36 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 25,245 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020069 · doc4.xml · derivative · entry 3 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,245 Underlying: Common Stock · 25,245 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1 · shares: On February 3, 2023, the reporting person was granted an award of 25,245 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 12,623 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 12,622 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 25,245 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 12,623 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 12,622 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 22:46 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000899243-23-004208 · doc4.xml · derivative · entry 2 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-02-02 F3 · derivative.exercise_date: The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 22:46 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-004208 · doc4.xml · derivative · entry 1 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. F2 · derivative.expiration_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 20:46 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $10.84 | $0.00 |
DisclosureSEC source: 0000899243-22-030735 · doc4.xml · derivative · entry 1 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-07-18 F1 · balance_after: On June 19, 2017, the Reporting Person was granted an option to purchase 70,000 shares of the Issuer's common stock. Subject to the Reporting Person's continued service to the Issuer through each applicable vesting date, the option vests and becomes exercisable in two equal installments upon the satisfaction of certain performance criteria. On September 8, 2022, the Issuer's Board of Directors determined that the performance criteria for the first installment were met, resulting in vesting of the option as to 35,000 shares. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 23:27 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantCOMMON STOCK | 47,619 | $3.15 | $149,999.85 |
DisclosureSEC source: 0000899243-22-025520 · doc4.xml · nonDerivative · entry 1 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,619 Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $7.38 | $0.00 |
DisclosureSEC source: 0000899243-22-005313 · doc4.xml · derivative · entry 1 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2032-02-03 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on February 4, 2023. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:47 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $26.34 | $0.00 |
DisclosureSEC source: 0000899243-21-005242 · doc4.xml · derivative · entry 1 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2031-02-03 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on February 4, 2022. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,562 | $0.00 Strike: $6.01 | $0.00 |
DisclosureSEC source: 0000899243-20-032667 · doc4.xml · derivative · entry 9 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,938 Underlying: Common Stock · 27,562 shares Expires 2029-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option has vested as to 25% of the shares on January 25, 2020. The remainder of the shares will vest or have vested in 12 equal quarterly installments thereafter. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,250 | $0.00 Strike: $9.89 | $0.00 |
DisclosureSEC source: 0000899243-20-032667 · doc4.xml · derivative · entry 8 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 26,250 shares Expires 2024-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option has vested as to 25% of the shares on January 26, 2018. The remainder of the shares will vest or have vested in 12 equal quarterly installments thereafter. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-20-032667 · doc4.xml · derivative · entry 7 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,000 shares Expires 2024-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 9,841 | $28.34 | $278,893.94 |
DisclosureSEC source: 0000899243-20-032667 · doc4.xml · nonDerivative · entry 6 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.145 to $28.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 26,265 | $27.56 | $723,863.40 |
DisclosureSEC source: 0000899243-20-032667 · doc4.xml · nonDerivative · entry 5 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,841 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.10 to $28.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 55,706 | $26.56 | $1,479,551.36 |
DisclosureSEC source: 0000899243-20-032667 · doc4.xml · nonDerivative · entry 4 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,106 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.07 to $27.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 27,562 | $6.01 | $165,647.62 |
DisclosureSEC source: 0000899243-20-032667 · doc4.xml · nonDerivative · entry 3 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 26,250 | $9.89 | $259,612.50 |
DisclosureSEC source: 0000899243-20-032667 · doc4.xml · nonDerivative · entry 2 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 26,000 | $0.71 | $18,460.00 |
DisclosureSEC source: 0000899243-20-032667 · doc4.xml · nonDerivative · entry 1 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 300,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0000899243-20-002419 · doc4.xml · derivative · entry 1 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-01-28 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on January 29, 2021. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 26, 2020 Filed Jan 28, 2020 21:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-002211 · doc4.xml · derivative · entry 2 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units are fully vested and do not have an expiration date. F2 · derivative.expiration_date: The restricted stock units are fully vested and do not have an expiration date. Read SEC document |
| January 26, 2020 Filed Jan 28, 2020 21:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCOMMON STOCK | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-002211 · doc4.xml · nonDerivative · entry 1 Henn Matthew R. · CIK 0001767321 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.